PMID- 9556193
OWN - NLM
STAT- MEDLINE
DCOM- 19980529
LR  - 20190826
IS  - 0302-2838 (Print)
IS  - 0302-2838 (Linking)
VI  - 33 Suppl 2
DP  - 1998
TI  - Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in 
      General Practice.
PG  - 28-33
AB  - The objectives of this open-labeled study were to assess the clinical 
      uroselectivity of alfuzosin in a long-term follow-up study in general practice. A 
      total of 3,228 patients with clinical benign prostatic hyperplasia (BPH) from 812 
      centers were included in a prospective 3-year open-labeled study and treated with 
      alfuzosin (immediate-release formulation) at the recommended dosage. Symptom 
      score (Boyarsky, modified) and a 20-item BPH-specific health related quality of 
      life (HRQL) score (Urolife BPH QoL 20), which included three questions on 
      sexuality, were self-administered at baseline, 3, 6, 12, 18, 24, 30 and 36 
      months. Symptom score was significantly reduced by 54% at 3 months and this 
      reduction was maintained up to 36 months; the HRQL score was significantly 
      improved by 45.4% at 12 months and this improvement was also maintained up to 36 
      months. Alfuzosin was well tolerated: the quantitative and qualitative 
      distribution of adverse events (AEs) was similar to that previously observed in 
      placebo-controlled studies. 4.2% of the patients dropped out due to AEs. This 
      study confirms the long-term safety profile of alfuzosin in general practice and 
      highlights the need to measure HRQL in the context of clinical uroselectivity.
FAU - Lukacs, B
AU  - Lukacs B
AD  - Urology Department, Hospital Tenon, Paris, France.
FAU - Grange, J C
AU  - Grange JC
FAU - McCarthy, C
AU  - McCarthy C
FAU - Comet, D
AU  - Comet D
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - Switzerland
TA  - Eur Urol
JT  - European urology
JID - 7512719
RN  - 0 (Adrenergic alpha-Antagonists)
RN  - 0 (Quinazolines)
RN  - 90347YTW5F (alfuzosin)
SB  - IM
MH  - Adrenergic alpha-Antagonists/adverse effects/*therapeutic use
MH  - Aged
MH  - Family Practice
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostatic Hyperplasia/*drug therapy
MH  - Quality of Life
MH  - Quinazolines/adverse effects/*therapeutic use
MH  - Safety
MH  - Sexuality/drug effects
EDAT- 1998/04/29 06:35
MHDA- 2000/10/06 11:01
CRDT- 1998/04/29 06:35
PHST- 1998/04/29 06:35 [pubmed]
PHST- 2000/10/06 11:01 [medline]
PHST- 1998/04/29 06:35 [entrez]
AID - eur3b028 [pii]
AID - 10.1159/000052231 [doi]
PST - ppublish
SO  - Eur Urol. 1998;33 Suppl 2:28-33. doi: 10.1159/000052231.